Correspondence to: Professor Ian R Whittle, Department of Clinical Neuroscience, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK; [email protected] _________________________ T he management of low grade glioma is one of the most controversial areas in clinical neurooncology. There are numerous reviews and editorials outlining the difficulties in management of these lesions. Ind...

The anticancer drugs screening program is a long and expensive process. It is estimated that only 5% of drugs entering clinical trials are approved by the FDA. Moreover, many of the drugs that enter clinical trials are often of limited use in clinical practice, and most cancers remain untreatable. Brain tumors are particularly difficult to treat due to the presence of the blood brain barrier th...

Serum-free culture methods for patient-derived primary glioma cultures, selecting for glioma stem-like cells (GSCs), are becoming the gold standard in neurooncology research. These GSCs can be implemented in drug screens to detect patient-specific responses, potentially bridging the translational gap to personalized medicine. Since numerous compounds are available, a rapid and reliable readout ...

Radiosurgery is a common approach for patients with brain tumors. After stereotactic radiosurgery (SRS), the differentiation between tumor progression and radiation effects (RE) can be difficult using current clinical criteria supplemented by computed tomography (CT) or magnetic resonance (MR) imaging (MRI). This is one of the greatest challenges in radiosurgical practice and indeed in neuroonc...

Abstract Purpose To provide guidance to clinicians regarding therapy for diffuse astrocytic and oligodendroglial tumors in adults. Methods ASCO the Society Neuro-Oncology convened an Expert Panel conducted a systematic review of literature. Results Fifty-nine randomized trials focusing on therapeutic management were identified. Recommendations Adults with newly diagnosed oligodendroglioma, isoc...

Abstract Disease relapse almost inevitably occurs in patients with adult-type diffuse glioma. Standard of care treatment options at tumor are still not well defined. Few studies indicate that the combination trofosfamide plus etoposide (T/E) may be feasible pediatric glioblastoma patients. We collected clinicopathological data from adult glioma treated Trofosfamide (100mg/m2/day) and Etoposide ...